Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 4Breast 4Thoracic 3Tumor-Agnostic 2Sarcoma 2Genitourinary 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Dermatofibrosarcoma 1Breast Neoplasms 1Bone Neoplasms 1Bone Diseases 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × saracatinib × Sarcoma × Clear all
NCT00659360 2018-06-29

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
17 enrolled 9 charts
GynecologicSarcoma

Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT00558272 2013-05-27

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

AstraZeneca

Phase 2 Completed
139 enrolled 23 charts
BreastGenitourinarySarcoma

Bone Diseases, Bone Neoplasms, Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡